

# Sebastian KÃ¼gler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4851796/publications.pdf>

Version: 2024-02-01

41  
papers

2,421  
citations

279798

23  
h-index

289244

40  
g-index

42  
all docs

42  
docs citations

42  
times ranked

4443  
citing authors

#	ARTICLE	IF	CITATIONS
1	Î±-Synuclein Impacts on Intrinsic Neuronal Network Activity Through Reduced Levels of Cyclic AMP and Diminished Numbers of Active Presynaptic Terminals. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, .	2.9	2
2	The relevance of synuclein autoantibodies as a biomarker for Parkinson's disease. <i>Molecular and Cellular Neurosciences</i> , 2022, 121, 103746.	2.2	8
3	Dopamine promotes the neurodegenerative potential of Î²-synuclein. <i>Journal of Neurochemistry</i> , 2021, 156, 674-691.	3.9	19
4	Dementia with Lewy bodies-associated Î³-synuclein mutations V70M and P123H cause mutation-specific neuropathological lesions. <i>Human Molecular Genetics</i> , 2021, 30, 247-264.	2.9	12
5	Optimized pharmacological control over the AAV-Gene-Switch vector for regulable gene therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 1-10.	4.1	5
6	Patterning inconsistencies restrict the true potential of dopaminergic neurons derived from human induced pluripotent stem cells. <i>Neural Regeneration Research</i> , 2021, 16, 692.	3.0	7
7	Systemic AAV6-synapsin-GFP administration results in lower liver biodistribution, compared to AAV1&2 and AAV9, with neuronal expression following ultrasound-mediated brain delivery. <i>Scientific Reports</i> , 2021, 11, 1934.	3.3	12
8	Neuronal Trans-differentiation by Transcription Factors Ascl1 and Nurr1: Induction of a Dopaminergic Neurotransmitter Phenotype in Cortical GABAergic Neurons. <i>Molecular Neurobiology</i> , 2020, 57, 249-260.	4.0	11
9	MRI-Guided Focused Ultrasound for Targeted Delivery of rAAV to the Brain. <i>Methods in Molecular Biology</i> , 2019, 1950, 177-197.	0.9	36
10	CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies. <i>Redox Biology</i> , 2019, 22, 101118.	9.0	34
11	Î²-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration. <i>Nature</i> , 2019, 566, 503-508.	27.8	109
12	Homogenous generation of dopaminergic neurons from multiple hiPSC lines by transient expression of transcription factors. <i>Cell Death and Disease</i> , 2019, 10, 898.	6.3	44
13	Strategy to enhance transgene expression in proximity of amyloid plaques in a mouse model of Alzheimer's disease. <i>Theranostics</i> , 2019, 9, 8127-8137.	10.0	22
14	Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. <i>Human Molecular Genetics</i> , 2019, 28, 31-50.	2.9	131
15	Probing the function of glycinergic neurons in the mouse respiratory network using optogenetics. <i>Respiratory Physiology and Neurobiology</i> , 2019, 265, 141-152.	1.6	18
16	A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	118
17	Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. <i>Redox Biology</i> , 2018, 14, 522-534.	9.0	125
18	Pathophysiological Consequences of Neuronal Î±-Synuclein Overexpression: Impacts on Ion Homeostasis, Stress Signaling, Mitochondrial Integrity, and Electrical Activity. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 49.	2.9	22

#	ARTICLE	IF	CITATIONS
19	Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free $\alpha$ GeneSwitch $\beta$ -vector. <i>Experimental Neurology</i> , 2018, 309, 79-90.	4.1	21
20	Pharmacologically Controlled Neurotrophic Factor Gene Therapy for Parkinson's Disease. , 2018, , 177-193.		1
21	A MicroRNA124 Target Sequence Restores Astrocyte Specificity of gfaABC1D-Driven Transgene Expression in AAV-Mediated Gene Transfer. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 13-25.	5.1	31
22	Long-Term Assessment of AAV-Mediated Zinc Finger Nuclease Expression in the Mouse Brain. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 142.	2.9	7
23	The mechanism of sirtuin 2 $\beta$ -mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. <i>PLoS Biology</i> , 2017, 15, e2000374.	5.6	114
24	Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 61-77.	5.4	209
25	Tissue-Specific Promoters in the CNS. <i>Methods in Molecular Biology</i> , 2016, 1382, 81-91.	0.9	15
26	Thalamocortical Connections Drive Intracortical Activation of Functional Columns in the Mismalaminated Reeler Somatosensory Cortex. <i>Cerebral Cortex</i> , 2015, 26, bhv257.	2.9	29
27	Dimerization propensities of Synucleins are not predictive for Synuclein aggregation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1658-1664.	3.8	15
28	Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease. <i>Human Molecular Genetics</i> , 2015, 24, 5451-5463.	2.9	43
29	Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. <i>Brain</i> , 2014, 137, 78-91.	7.6	112
30	Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2014, 65, 35-42.	4.4	50
31	$\beta$ -synuclein aggregates and induces neurodegeneration in dopaminergic neurons. <i>Annals of Neurology</i> , 2013, 74, 109-118.	5.3	58
32	Adeno-associated Virus-mediated, Mifepristone-regulated Transgene Expression in the Brain. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e106.	5.1	44
33	Efficient Gene Therapy for Parkinson's Disease Using Astrocytes as Hosts for Localized Neurotrophic Factor Delivery. <i>Molecular Therapy</i> , 2012, 20, 534-543.	8.2	82
34	Aggregation of $\beta$ -Synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. <i>Acta Neuropathologica</i> , 2012, 123, 671-683.	7.7	96
35	Probing the Functional Equivalence of Otoferlin and Synaptotagmin 1 in Exocytosis. <i>Journal of Neuroscience</i> , 2011, 31, 4886-4895.	3.6	94
36	Dendritic Degeneration, Neurovascular Defects, and Inflammation Precede Neuronal Loss in a Mouse Model for Tau-Mediated Neurodegeneration. <i>American Journal of Pathology</i> , 2011, 179, 2001-2015.	3.8	105

#	ARTICLE	IF	CITATIONS
37	Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons. <i>Acta Neuropathologica</i> , 2011, 121, 475-485.	7.7	51
38	AAV-Tau Mediates Pyramidal Neurodegeneration by Cell-Cycle Re-Entry without Neurofibrillary Tangle Formation in Wild-Type Mice. <i>PLoS ONE</i> , 2009, 4, e7280.	2.5	71
39	Pre-fibrillar $\alpha$ -synuclein variants with impaired $\alpha$ -structure increase neurotoxicity in Parkinson's disease models. <i>EMBO Journal</i> , 2009, 28, 3256-3268.	7.8	411
40	Comparison of test systems for RNA interference. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 245-253.	2.1	10
41	Increased protein expression from adenoviral shuttle plasmids and vectors by insertion of a small chimeric intron sequence. <i>Journal of Virological Methods</i> , 2004, 122, 73-77.	2.1	15